Int J Med Sci 2022; 19(14):1989-1994. doi:10.7150/ijms.78182 This issue Cite

Research Paper

Prognostic value of pretreatment systemic inflammatory markers in patients with stage I endometrial cancer

Jung Hwan Ahn1, Sung Jong Lee2, Joo Hee Yoon3, Dong Choon Park3, Sang Il Kim3✉

1. Department of Obstetrics and Gynecology, Yonsei University Wonju College of Medicine, Republic of Korea.
2. Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
3. Department of Obstetrics and Gynecology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Citation:
Ahn JH, Lee SJ, Yoon JH, Park DC, Kim SI. Prognostic value of pretreatment systemic inflammatory markers in patients with stage I endometrial cancer. Int J Med Sci 2022; 19(14):1989-1994. doi:10.7150/ijms.78182. https://www.medsci.org/v19p1989.htm
Other styles

File import instruction

Abstract

Graphic abstract

Objective: Evaluate the prognostic value of monocyte-lymphocyte ratio (MLR) in patients with stage I endometrial cancer.

Method: Data from 225 patients with stage I endometrioid endometrial cancer who underwent surgical resection between January 2010 and December 2020 were reviewed. The receiver operating characteristic (ROC) curves were generated for the neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and MLR. Optimal cut-off values were determined as the points at which the Youden index (sensitivity + specificity - 1) was maximal. Based on the results of the ROC curve analysis, the patients were grouped into high MLR and low MLR groups. Recurrence rate, and disease-free survival were compared between the two groups. The prognostic factors were investigated using univariate and multivariate Cox proportional hazards model.

Results: The optimal cut-off value of MLR was 0.220 (AUC, 0.835; p < 0.001). Significantly more patients in the high MLR group experienced recurrence (20.3% vs. 1.9%, p < 0.0001). In multivariate analysis, grade, depth of myometrial invasion, adjuvant RT, and high MLR were independent prognostic factors for disease-free survival.

Conclusion: Elevated MLR was significantly associated poor clinical outcomes in patients with stage I endometrioid endometrial cancer. Our findings suggest that MLR may be clinically reliable and useful as an independent prognostic marker for patients with stage I endometrioid endometrial cancer.

Keywords: endometrial cancer, uterine cancer, systemic inflammation reponse, adverse risk factors, monocyte-lymphocyte ratio


Citation styles

APA
Ahn, J.H., Lee, S.J., Yoon, J.H., Park, D.C., Kim, S.I. (2022). Prognostic value of pretreatment systemic inflammatory markers in patients with stage I endometrial cancer. International Journal of Medical Sciences, 19(14), 1989-1994. https://doi.org/10.7150/ijms.78182.

ACS
Ahn, J.H.; Lee, S.J.; Yoon, J.H.; Park, D.C.; Kim, S.I. Prognostic value of pretreatment systemic inflammatory markers in patients with stage I endometrial cancer. Int. J. Med. Sci. 2022, 19 (14), 1989-1994. DOI: 10.7150/ijms.78182.

NLM
Ahn JH, Lee SJ, Yoon JH, Park DC, Kim SI. Prognostic value of pretreatment systemic inflammatory markers in patients with stage I endometrial cancer. Int J Med Sci 2022; 19(14):1989-1994. doi:10.7150/ijms.78182. https://www.medsci.org/v19p1989.htm

CSE
Ahn JH, Lee SJ, Yoon JH, Park DC, Kim SI. 2022. Prognostic value of pretreatment systemic inflammatory markers in patients with stage I endometrial cancer. Int J Med Sci. 19(14):1989-1994.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image